Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO study

European Journal of Cancer

Volumn 45, Issue 11, 2009, Pages 1999-2006

  Koopman, Miriam ^a   Venderbosch, Sabine ^a   van Tinteren, Harm ^b   Ligtenberg, Marjolijn J ^a   Nagtegaal, Iris ^a   Van Krieken, Johan H ^a   Punt, Cornelis J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Advanced colorectal cancer; Capecitabine; Chemotherapy; DPD; ERCC1; Irinotecan; OPRT; Prognostic and predictive markers; TP; TS

Indexed keywords

BIOLOGICAL MARKER; CAPECITABINE; DIHYDROPYRIMIDINE DEHYDROGENASE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; IRINOTECAN; OROTATE PHOSPHORIBOSYLTRANSFERASE; OXALIPLATIN; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE; TUMOR MARKER;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL PRACTICE; COLORECTAL CANCER; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION AND FORECASTING; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; STROMA CELL; SURVIVAL TIME; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CLINICAL TRIALS, PHASE III AS TOPIC; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DIHYDROURACIL DEHYDROGENASE (NADP); DISEASE-FREE SURVIVAL; DNA-BINDING PROTEINS; ENDONUCLEASES; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; OROTATE PHOSPHORIBOSYLTRANSFERASE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL RATE; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 67649304464     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.04.017     Document Type: Article

References (32)

1. Punt C.J. New options and old dilemmas in the treatment of patients with advanced colorectal cancer. Ann Oncol 15 (2004) 1453-1459
2. McShane L.M., Altman D.G., Sauerbrei W., Taube S.E., Gion M., and Clark G.M. REporting recommendations for tumour MARKer prognostic studies (REMARK). Eur J Cancer 41 (2005) 1690-1696
3. Meropol N.J., Gold P.J., Diasio R.B., et al. Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 24 (2006) 4069-4077
4. Popat S., Matakidou A., and Houlston R.S. Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol 22 (2004) 529-536
5. Salonga D., Danenberg K.D., Johnson M., et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 6 (2000) 1322-1327
6. Tokunaga Y., Sasaki H., and Saito T. Clinical role of orotate phosphoribosyl transferase and dihydropyrimidine dehydrogenase in colorectal cancer treated with postoperative fluoropyrimidine. Surgery 141 (2007) 346-353
7. Fink D., Nebel S., Aebi S., et al. The role of DNA mismatch repair in platinum drug resistance. Cancer Res 56 (1996) 4881-4886
8. Braun M.S., Richman S.D., Quirke P., et al. Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. J Clin Oncol 26 (2008) 2690-2698
9. Ruzzo A., Graziano F., Loupakis F., et al. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol 25 (2007) 1247-1254
10. Shirota Y., Stoehlmacher J., Brabender J., et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 19 (2001) 4298-4304
11. Koopman M., Antonini N.F., Douma J., et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet 370 (2007) 135-142
12. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 (2000) 205-216
13. With Applications to Linear models, Logistic Regression, and Survival Analyses. 2nd printing 2006 ed. Springer; 2009.
14. Koopman M., Kortman G.A., Mekenkamp L., et al. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br J Cancer 100 (2009) 266-273
15. Beck A., Etienne M.C., Cheradame S., et al. A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil. Eur J Cancer 30 (1994) 1517-1522
16. Ciaparrone M., Quirino M., Schinzari G., et al. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil. Oncology 70 (2006) 366-377
17. Jensen S.A., Vainer B., and Sorensen J.B. The prognostic significance of thymidylate synthase and dihydropyrimidine dehydrogenase in colorectal cancer of 303 patients adjuvantly treated with 5-fluorouracil. Int J Cancer 120 (2007) 694-701
18. Lassmann S., Hennig M., Rosenberg R., et al. Thymidine phosphorylase, dihydropyrimidine dehydrogenase and thymidylate synthase mRNA expression in primary colorectal tumors-correlation to tumor histopathology and clinical follow-up. Int J Colorectal Dis 21 (2006) 238-247
19. Soong R., Shah N., Salto-Tellez M., et al. Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy. Ann Oncol 19 (2008) 915-919
20. Tokunaga Y., Takahashi K., and Saito T. Clinical role of thymidine phosphorylase and dihydropyrimidine dehydrogenase in colorectal cancer treated with postoperative fluoropyrimidine. Hepatogastroenterology 52 (2005) 1715-1721
21. Cao S., Durrani F.A., and Rustum Y.M. Synergistic antitumor activity of capecitabine in combination with irinotecan. Clin Colorectal Cancer 4 (2005) 336-343
22. Pavillard V., Formento P., Rostagno P., et al. Combination of irinotecan (CPT11) and 5-fluorouracil with an analysis of cellular determinants of drug activity. Biochem Pharmacol 56 (1998) 1315-1322
23. Xu J.M., Azzariti A., Tommasi S., et al. Combination of 5-fluorouracil and irinotecan on modulation of thymidylate synthase and topoisomerase I expression and cell cycle regulation in human colon cancer LoVo cells: clinical relevance. Clin Colorectal Cancer 2 (2002) 182-188
24. Yanagisawa Y., Maruta F., Iinuma N., et al. Modified Irinotecan/5FU/Leucovorin therapy in advanced colorectal cancer and predicting therapeutic efficacy by expression of tumor-related enzymes. Scand J Gastroenterol 42 (2007) 477-484
25. Karnoub A.E., Dash A.B., Vo A.P., et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449 (2007) 557-563
26. Kim B.G., Li C., Qiao W., et al. Smad4 signalling in T cells is required for suppression of gastrointestinal cancer. Nature 441 (2006) 1015-1019
27. Saito S., Tsuno N., Nagawa H., et al. Expression of platelet-derived endothelial cell growth factor correlates with good prognosis in patients with colorectal carcinoma. Cancer 88 (2000) 42-49
28. Paradiso A., Xu J., Mangia A., et al. Topoisomerase-I, thymidylate synthase primary tumour expression and clinical efficacy of 5-FU/CPT-11 chemotherapy in advanced colorectal cancer patients. Int J Cancer 111 (2004) 252-258
29. Cao D., Russell R.L., Zhang D., Leffert J.J., and Pizzorno G. Uridine phosphorylase (-/-) murine embryonic stem cells clarify the key role of this enzyme in the regulation of the pyrimidine salvage pathway and in the activation of fluoropyrimidines. Cancer Res 62 (2002) 2313-2317
30. Ciccolini J., Evrard A., and Cuq P. Thymidine phosphorylase and fluoropyrimidines efficacy: a Jekyll and Hyde story. Curr Med Chem Anticancer Agents 4 (2004) 71-81
31. Duffy M.J., van Dalen A., Haglund C., et al. Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer 43 (2007) 1348-1360
32. Locker G.Y., Hamilton S., Harris J., et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 24 (2006) 5313-5327